Abstract
Background: Statin treatment exhibits a beneficial effect on non-alcoholic fatty liver disease (NAFLD) and on cardiovascular disease (CVD) in patients with NAFLD.
Objective: The aim of this review is to summarize the role of proprotein convertase subtilisin kexin type- 9(PCSK9) in the pathogenesis of NAFLD and discuss the effects of the new hypolipidaemic drugs PCSK9 inhibitors on NAFLD.
Results: Data indicates that high intrahepatic or circulating PCSK9 levels increase muscle and liver lipid storage, adipose energy storage and hepatic fatty acids, as well as triglycerides storage and secretion, thus contributing to the pathogenesis of NAFLD. The findings of animal and human studies, aiming to reduce PCSK9 with inhibitors (human IGG antibodies, antisense particles against PCSK9 mRNA, and small anti PCSK9 antibodies) point towards liver protection from NAFLD through inhibition of PCSK9 expression in the induction of degradation of hepatic HNF1a protein, insulin resistance (IR), and other mechanisms.
Conclusions: The use of PCSK9 inhibitors ameliorates NAFLD, aside from beneficial effects on CVD and independently of low density lipoprotein cholesterol level reduction.
Keywords: PCSK9 inhibitors, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, familial hypercholesterolemia, statin, cardiovascular disease.
Current Pharmaceutical Design
Title:The Role of PCSK9 in the Pathogenesis of Non-alcoholic Fatty Liver Disease and the Effect of PCSK9 Inhibitors
Volume: 24 Issue: 31
Author(s): Eleni Theocharidou*, Marianna Papademetriou, Andromachi Reklou, Alexandros Sachinidis, Chrisoula Boutari and Olga Giouleme
Affiliation:
- Institute of Liver Studies, King's College Hospital, Denmark Hill, SE5 9RS,United Kingdom
Keywords: PCSK9 inhibitors, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, familial hypercholesterolemia, statin, cardiovascular disease.
Abstract: Background: Statin treatment exhibits a beneficial effect on non-alcoholic fatty liver disease (NAFLD) and on cardiovascular disease (CVD) in patients with NAFLD.
Objective: The aim of this review is to summarize the role of proprotein convertase subtilisin kexin type- 9(PCSK9) in the pathogenesis of NAFLD and discuss the effects of the new hypolipidaemic drugs PCSK9 inhibitors on NAFLD.
Results: Data indicates that high intrahepatic or circulating PCSK9 levels increase muscle and liver lipid storage, adipose energy storage and hepatic fatty acids, as well as triglycerides storage and secretion, thus contributing to the pathogenesis of NAFLD. The findings of animal and human studies, aiming to reduce PCSK9 with inhibitors (human IGG antibodies, antisense particles against PCSK9 mRNA, and small anti PCSK9 antibodies) point towards liver protection from NAFLD through inhibition of PCSK9 expression in the induction of degradation of hepatic HNF1a protein, insulin resistance (IR), and other mechanisms.
Conclusions: The use of PCSK9 inhibitors ameliorates NAFLD, aside from beneficial effects on CVD and independently of low density lipoprotein cholesterol level reduction.
Export Options
About this article
Cite this article as:
Theocharidou Eleni *, Papademetriou Marianna , Reklou Andromachi , Sachinidis Alexandros, Boutari Chrisoula and Giouleme Olga , The Role of PCSK9 in the Pathogenesis of Non-alcoholic Fatty Liver Disease and the Effect of PCSK9 Inhibitors, Current Pharmaceutical Design 2018; 24 (31) . https://dx.doi.org/10.2174/1381612824666181010123127
DOI https://dx.doi.org/10.2174/1381612824666181010123127 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
From NAFLD to NASH and HCC: Pathogenetic Mechanisms and Therapeutic Insights
Current Pharmaceutical Design Peroxisome Proliferator-Activated Receptor-γ in Vascular Biology
Cardiovascular & Hematological Disorders-Drug Targets Therapeutic Effects of Physical Exercise and the Mesenchymal Stem Cell Secretome by Modulating Neuroinflammatory Response in Multiple Sclerosis
Current Stem Cell Research & Therapy Epigenetic Inheritance of Paternally Expressed Imprinted Genes in the Testes of ICSI Mice
Current Pharmaceutical Design Colorimetric Detection and Adsorption of Mercury Using Silver Nanoparticles: A Bibliographic and Patent Review
Nanoscience & Nanotechnology-Asia Structure-Based Drug Discovery Accelerated by Many-Core Devices
Current Drug Targets Prediction and Monitoring of Therapeutic Response by Molecular Imaging
Current Medical Imaging Ligand-Based Peptide Design and Combinatorial Peptide Libraries to Target G Protein-Coupled Receptors
Current Pharmaceutical Design Botanical Therapeutics (Part II): Antimicrobial and In Vitro Anticancer Activity against MCF7 Human Breast Cancer Cells of Chamomile, Parsley and Celery Alcoholic Extracts
Anti-Cancer Agents in Medicinal Chemistry Size-Dependent Differences in Biodistribution of Titanium Dioxide Nanoparticles After Sub-Acute Intragastric Administrations to Rats
Current Nanoscience Mitotic and Gender Parallels in Alzheimer Disease: Therapeutic Opportunities
Current Drug Targets Photochemical Advanced Oxidation Processes for Water and Wastewater Treatment
Recent Patents on Engineering Current Status of Computer-Aided Drug Design for Type 2 Diabetes
Current Computer-Aided Drug Design Central Amylin Signaling and the Regulation of Energy Homeostasis
Current Pharmaceutical Design Does Metabolic Syndrome or its Individual Components Affect Pain and Function in Knee Osteoarthritis Women?
Current Rheumatology Reviews Functional Autoradiography Shows Unaltered Cannabinoid CB1 Receptor Signalling in Hippocampus and Cortex of APP/PS1 Transgenic Mice
CNS & Neurological Disorders - Drug Targets The Role of Genes (and Environmental Stress) in Depression: An Update
Current Psychiatry Reviews Natural Polyphenols and Cardioprotection
Mini-Reviews in Medicinal Chemistry <i>In Vitro</i> Antioxidant and Alpha-glucosidase Inhibition Activity of <i>Polygonatum verticillatum</i> of Karnali, Nepal
Current Drug Therapy Glycogen Metabolism and Brain Pathologies
Central Nervous System Agents in Medicinal Chemistry